Lisa E Gralinski

List of Publications by Citations

59 papers	9,280 citations	38 h-index	67 g-index
67 ext. papers	12,371 ext. citations	16.6 avg, IF	6.68 L-index

#	Paper	IF	Citations
59	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Science Translational Medicine*, **2017**, 9,	17.5	983
58	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. *Cell*, **2020**, 182, 429-446.e14	56.2	710
57	Return of the Coronavirus: 2019-nCoV. *Viruses*, **2020**, 12,	6.2	660
56	Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature*, **2020**, 584, 443-449	50.4	609
55	A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. *Nature Medicine*, **2015**, 21, 1508-13	50.5	529
54	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science*, **2020**, 370, 1464-1468	33.3	517
53	Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. *MBio*, **2018**, 9,	7.8	431
52	Animal models for COVID-19. *Nature*, **2020**, 586, 509-515	50.4	377
51	A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. *Journal of Virology*, **2011**, 85, 12201-15	6.6	346
50	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. *Nature*, **2020**, 586, 560-566	50.4	299
49	SARS-like WIV1-CoV poised for human emergence. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 3048-53	11.5	279
48	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. *Cell Reports*, **2020**, 32, 107940	10.6	260
47	Molecular pathology of emerging coronavirus infections. *Journal of Pathology*, **2015**, 235, 185-95	9.4	228
46	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. *Cell*, **2020**, 183, 1070-1085.e12	56.2	224
45	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell*, **2020**, 183, 169-184.e13	56.2	221
44	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. *Cell*, **2020**, 183, 1367-1382.e17	56.2	217
43	Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. *MBio*, **2013**, 4,	7.8	204

42	Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. *MBio*, **2014**, 5, e01174-14	7.8	199
41	Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2ao-methyltransferase activity. *Journal of Virology*, **2014**, 88, 4251-64	6.6	157
40	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. *Science*, **2021**, 371, 823-829	33.3	157
39	Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. *PLoS Pathogens*, **2013**, 9, e1003196	7.6	141
38	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. *Nature*, **2021**, 591, 451-457	50.4	131
37	Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *Journal of Virology*, **2020**, 94,	6.6	116
36	The Mouse Universal Genotyping Array: From Substrains to Subspecies. *G3: Genes, Genomes, Genetics*, **2015**, 6, 263-79	3.2	109
35	Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. *PLoS Genetics*, **2015**, 11, e1005504	6	103
34	MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E1012-E1021	11.5	100
33	MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis. *MBio*, **2017**, 8,	7.8	99
32	Release of severe acute respiratory syndrome coronavirus nuclear import block enhances host transcription in human lung cells. *Journal of Virology*, **2013**, 87, 3885-902	6.6	97
31	Annotation of long non-coding RNAs expressed in collaborative cross founder mice in response to respiratory virus infection reveals a new class of interferon-stimulated transcripts. *RNA Biology*, **2014**, 11, 875-90	4.8	74
30	Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis. *MSphere*, **2017**, 2,	5	71
29	Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. *Journal of Virology*, **2011**, 85, 217-30	6.6	61
28	A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures **2020**,		58
27	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 29832-29838	11.5	57
26	Allelic Variation in the Toll-Like Receptor Adaptor Protein Contributes to SARS-Coronavirus Pathogenesis in Mice. *G3: Genes, Genomes, Genetics*, **2017**, 7, 1653-1663	3.2	50
25	Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines. *Journal of Virology*, **2018**, 92,	6.6	48

24	A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. *MBio*, **2014**, 5, e00047-14	7.8	47
23	The effect of inhibition of PP1 and TNF□signaling on pathogenesis of SARS coronavirus. *BMC Systems Biology*, **2016**, 10, 93	3.5	45
22	SARS-CoV-2 D614G Variant Exhibits Enhanced Replication and Earlier Transmission **2020**,		41
21	New Metrics for Evaluating Viral Respiratory Pathogenesis. *PLoS ONE*, **2015**, 10, e0131451	3.7	36
20	Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals **2020**,		24
19	Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models **2020**,		19
18	Content and Performance of the MiniMUGA Genotyping Array: A New Tool To Improve Rigor and Reproducibility in Mouse Research. *Genetics*, **2020**, 216, 905-930	4	17
17	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. *Nature Communications*, **2021**, 12, 3587	17.4	17
16	Genomic profiling of collaborative cross founder mice infected with respiratory viruses reveals novel transcripts and infection-related strain-specific gene and isoform expression. *G3: Genes, Genomes, Genetics*, **2014**, 4, 1429-44	3.2	16
15	An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 **2020**,		11
14	Mucin 4 Protects Female Mice from Coronavirus Pathogenesis		10
13	Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 **2020**,		10
12	The Role of EGFR in Influenza Pathogenicity: Multiple Network-Based Approaches to Identify a Key Regulator of Non-lethal Infections. *Frontiers in Cell and Developmental Biology*, **2019**, 7, 200	5.7	9
11	Complex Genetic Architecture Underlies Regulation of Influenza-A-Virus-Specific Antibody Responses in the Collaborative Cross. *Cell Reports*, **2020**, 31, 107587	10.6	9
10	Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. *PLoS Pathogens*, **2021**, 17, e1009287	7.6	8
9	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 delta infection.. *Science Immunology*, **2022**, eabo0226	28	4
8	Immune Predictors of Mortality After Ribonucleic Acid Virus Infection. *Journal of Infectious Diseases* , **2020**, 221, 882-889	7	3
7	Combination attenuation offers strategy for live-attenuated coronavirus vaccines		3

6	Trypsin treatment unlocks barrier for zoonotic coronaviruses infection		3
5	Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses. **2022**,		3
4	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. *Journal of Virology*, **2021**, 95, e0097421	6.6	3
3	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. **2022**,		2
2	Unfolded Protein Response Inhibition Reduces Middle East Respiratory Syndrome Coronavirus-Induced Acute Lung Injury. *MBio*, **2021**, 12, e0157221	7.8	1
1	Coagulation and wound repair during COVID-19. *Journal of Heart and Lung Transplantation*, **2021**, 40, 1076-1081	5.8	0